Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 09:03:47 2024-07-12 am EDT			5-day change	1st Jan Change
1.307 ^GBX	+2.62%		+0.03%	-43.16%

Jun. 17	Hemogenyx Pharmaceuticals updates on leukemia treatment	AN
Jun. 17	Hemogenyx Pharmaceuticals plc Announces Operations Update	CI

Hemogenyx completes process run for HEMO-CAR-T manufacture

January 23, 2023 at 12:00 pm EST

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Completes third process qualification run for the manufacture of HEMO-CAR-T cells. Says the HEMO-CAR-T cells will be tested by third party to ensure quality. The three process runs are required by the US Food & Drug Administration to begin clinical trials. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the investigational new drug submission pack. HEMO-CAR-T cells are being developed the potential treatment of acute myeloid leukemia, a blood and bone marrow cancer.

Current stock price: 3.30 pence, closing 2.3% higher

12-month change: more than doubled from 1.60p

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals updates on leukemia treatment	Jun. 17	AN
Hemogenyx Pharmaceuticals plc Announces Operations Update	Jun. 17	CI
EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	Apr. 25	AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	Feb. 29	AN
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	Feb. 29	MT
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	Feb. 16	MT
Hemogenyx shares rise on potential for CBR to treat brain diseases	Feb. 16	AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	Feb. 16	CI
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	Feb. 14	MT
Hemogenyx says CBR can be used intranasally to treat viral infections	Feb. 14	AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	Feb. 09	AN
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	Feb. 09	MT
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	Feb. 09	CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	Feb. 02	MT
Hemogenyx hails US patent application progress	Feb. 02	AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	Feb. 02	CI
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	Jan. 16	AN
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	Jan. 16	MT
Hemogenyx Pharmaceuticals completes process qualification run	Jan. 08	AN
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	Jan. 08	MT
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	Jan. 08	CI
Upland Resources completes technical study at Sarawak	Nov. 28	AN
Hemogenyx Platform Shows Potential for Blood Cancer Treatment; Shares Climb	Nov. 27	MT
Hemogenyx shares up as says CBR platform a potential cancer treatment	Nov. 27	AN

Chart Hemogenyx Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOGENYX PHARMACEUTICALS PLC	-43.16%	22.08M
VERTEX PHARMACEUTICALS INCORPORATED	+21.99%	127B
REGENERON PHARMACEUTICALS, INC.	+24.57%	117B
ARGENX SE	+26.81%	27.77B
BIONTECH SE	-17.96%	20.44B
GENMAB A/S	-14.64%	16.62B
BEIGENE, LTD.	-12.96%	15.92B
WUXI APPTEC CO., LTD.	-46.65%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+12.80%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.73%	14.38B

Bio Therapeutic Drugs